These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32554756)

  • 1. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.
    Patel SD; Bono TR; Rowe SM; Solomon GM
    Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32554756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
    Shi J; Li H; Yuan C; Luo M; Wei J; Liu X
    Oxid Med Cell Longev; 2018; 2018():6567578. PubMed ID: 29849907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD.
    Martinez-Garcia MA; Sierra-Párraga JM; Quintana E; López-Campos JL
    J Cyst Fibros; 2022 Sep; 21(5):741-744. PubMed ID: 35551858
    [No Abstract]   [Full Text] [Related]  

  • 4. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Cantin AM
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S150-5. PubMed ID: 27115950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.
    Mall MA; Criner GJ; Miravitlles M; Rowe SM; Vogelmeier CF; Rowlands DJ; Schoenberger M; Altman P
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 37003609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
    Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
    Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
    Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
    Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.
    Raju SV; Solomon GM; Dransfield MT; Rowe SM
    Clin Chest Med; 2016 Mar; 37(1):147-58. PubMed ID: 26857776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction.
    Rasmussen JE; Sheridan JT; Polk W; Davies CM; Tarran R
    J Biol Chem; 2014 Mar; 289(11):7671-81. PubMed ID: 24448802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
    Perrem L; Ratjen F
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unified Airway-Cystic Fibrosis.
    Cho DY; Grayson JW; Woodworth BA
    Otolaryngol Clin North Am; 2023 Feb; 56(1):125-136. PubMed ID: 36266104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
    Kaza N; Lin VY; Stanford D; Hussain SS; Falk Libby E; Kim H; Borgonovi M; Conrath K; Mutyam V; Byzek SA; Tang LP; Trombley JE; Rasmussen L; Schoeb T; Leung HM; Tearney GJ; Raju SV; Rowe SM
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34916262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid therapeutic advances in CFTR modulator science.
    Clancy JP
    Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.
    Sloane PA; Shastry S; Wilhelm A; Courville C; Tang LP; Backer K; Levin E; Raju SV; Li Y; Mazur M; Byan-Parker S; Grizzle W; Sorscher EJ; Dransfield MT; Rowe SM
    PLoS One; 2012; 7(6):e39809. PubMed ID: 22768130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Mall MA
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.
    Dransfield MT; Wilhelm AM; Flanagan B; Courville C; Tidwell SL; Raju SV; Gaggar A; Steele C; Tang LP; Liu B; Rowe SM
    Chest; 2013 Aug; 144(2):498-506. PubMed ID: 23538783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoke and CFTR: implications in the pathogenesis of COPD.
    Rab A; Rowe SM; Raju SV; Bebok Z; Matalon S; Collawn JF
    Am J Physiol Lung Cell Mol Physiol; 2013 Oct; 305(8):L530-41. PubMed ID: 23934925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function.
    Bodas M; Silverberg D; Walworth K; Brucia K; Vij N
    Antioxid Redox Signal; 2017 Sep; 27(7):433-451. PubMed ID: 28006950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.
    Solomon GM; Raju SV; Dransfield MT; Rowe SM
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2(Suppl 2):S169-76. PubMed ID: 27115953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential systemic effects of acquired CFTR dysfunction in COPD.
    Miravitlles M; Criner GJ; Mall MA; Rowe SM; Vogelmeier CF; Hederer B; Schoenberger M; Altman P
    Respir Med; 2024 Jan; 221():107499. PubMed ID: 38104786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.